- Home
- KIDS vs AUTL Comparison
KIDS vs AUTL Comparison
Compare KIDS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- AUTL
- Stock Information
- Founded
- KIDS 2007
- AUTL 2014
- Country
- KIDS United States
- AUTL United Kingdom
- Employees
- KIDS N/A
- AUTL N/A
- Industry
- KIDS Medical/Dental Instruments
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIDS Health Care
- AUTL Health Care
- Exchange
- KIDS Nasdaq
- AUTL Nasdaq
- Market Cap
- KIDS 629.1M
- AUTL 609.4M
- IPO Year
- KIDS 2017
- AUTL 2018
- Fundamental
- Price
- KIDS $27.16
- AUTL $2.22
- Analyst Decision
- KIDS Buy
- AUTL Strong Buy
- Analyst Count
- KIDS 7
- AUTL 3
- Target Price
- KIDS $36.71
- AUTL $10.20
- AVG Volume (30 Days)
- KIDS 319.1K
- AUTL 1.4M
- Earning Date
- KIDS 03-05-2025
- AUTL 03-13-2025
- Dividend Yield
- KIDS N/A
- AUTL N/A
- EPS Growth
- KIDS N/A
- AUTL N/A
- EPS
- KIDS N/A
- AUTL N/A
- Revenue
- KIDS $189,673,000.00
- AUTL $10,091,000.00
- Revenue This Year
- KIDS $39.07
- AUTL $851.83
- Revenue Next Year
- KIDS $18.33
- AUTL $264.18
- P/E Ratio
- KIDS N/A
- AUTL N/A
- Revenue Growth
- KIDS 33.47
- AUTL 82.71
- 52 Week Low
- KIDS $21.02
- AUTL $2.07
- 52 Week High
- KIDS $35.99
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- KIDS 67.30
- AUTL 38.18
- Support Level
- KIDS $22.63
- AUTL $2.18
- Resistance Level
- KIDS $25.06
- AUTL $2.38
- Average True Range (ATR)
- KIDS 1.45
- AUTL 0.16
- MACD
- KIDS 0.49
- AUTL 0.01
- Stochastic Oscillator
- KIDS 98.73
- AUTL 7.94
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.